Six months on from the Falsified Medicines Directive (FMD) Oliver Pittock, managing director at Valley Northern discusses the status of the directive and the next steps for success.
On the back of changing regulations for pharmaceutical security in the supply chain, we speak to Carlos Ruiz Martinez, pharma operations leader at Almirall to find out how companies are coping.
European Pharmaceutical Manufacturer editor Reece Armstrong sits down with Neil Gleghorn, CEO of labelling provider Kallik, to discuss compliance challenges for manufacturers and the threat of counterfeit medicines.
In this article, Scott McDougall, co-founder and registered manager of The Independent Pharmacy outlines five technological advancements that are taking the fight to fake drugs.
In this whitepaper, Christoph Krähenbühl, senior director of Excellis Europe, explains the challenge new Russian traceability regulations present to the pharma industry.
Tatsiana Levdikova, content marketer at OpenLedger ApS, a blockchain development company, writes about the opioid epidemic in the US and if blockchain is the answer.
Stanley Chia, senior vice president at e-invoicing supplier, Tungsten Network, details the importance of secure supply chains in the age of the counterfeit drug.
In advance of new European measures to help reduce counterfeit medicines, Wayne Miller, healthcare director EMEA at Zebra Technologies, asks if the pharmaceutical supply chain is ready for true medicine traceability.
Ben Jones, technical manager, global serialisation services at PCI Pharma Services, discusses the complex world of serialisation and what strategies pharma companies can implement.
